Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-year Follow-up with Successful Sorafenib Treatment

Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-year Follow-up with Successful Sorafenib Treatment

Hereditary forms of medullary thyroid carcinoma (MTC) are rare. Different phenotypes with the same mutation may be due to differences in the timing of rearranged during transfection (RET) activation steps, additional mutations in other regions of the gene, or the co-occurrence of germline and somati...

Full description

Saved in:
Bibliographic Details
Main Authors: Sirmen Kızılcan Çetin, Zeynep Şıklar, Elif Özsu, Ayşegül Ceran, Koray Ceyhan, Zehra Aycan, Ayça Kırmızı, Handan Dinçaslan, Emel Ünal, Merih Berberoğlu
Format: Article
Language:English
Published: Galenos Yayincilik 2025-09-01
Series:JCRPE
Subjects:
medullary thyroid carcinoma
ret
sorafenib
Online Access:https://www.jcrpe.org/articles/familial-clinical-heterogeneity-of-medullary-thyroid-cancer-with-germline-lessemgreaterretlessemgreater-s891a-protooncogene-mutation-7-year-follow-up-with-successful-sorafenib-treatment/doi/jcrpe.galenos.2023.2023-7-13
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.jcrpe.org/articles/familial-clinical-heterogeneity-of-medullary-thyroid-cancer-with-germline-lessemgreaterretlessemgreater-s891a-protooncogene-mutation-7-year-follow-up-with-successful-sorafenib-treatment/doi/jcrpe.galenos.2023.2023-7-13

Similar Items